Key result
Chronic ergotamine use linked to severe multivessel valvular thickening and regurgitation.
Case Report (n=1)
Highlights a case of severe multi-valvular insufficiency secondary to chronic ergotamine tartrate exposure.
Answers are grounded in this paper and cite their sources.
Ergotamine may induce valvular dysfunction; leaves open causal confirmation and risk magnitude in larger cohorts.
A 67-year-old woman reported having progressive shortness of breath over several months, three years after undergoing aortic-valve replacement for aortic insufficiency. The patient had migraine headaches for which she had received 2 mg of ergotamine tartrate daily for many years. On physical examination, her blood pressure was 170/95 mm Hg. She had elevated jugular venous pressure, and grade 2/6 systolic and diastolic murmurs were noted along the right sternal border. The results of laboratory analysis for 5-hydroxyindoleacetic acid were normal. Echocardiography showed a normal aortic-valve prosthesis and thickened mitral, pulmonary, and tricuspid valves with severe insufficiency. Cardiac catheterization revealed elevated . . .
No takes yet. Share an insight, caveat, or question.
Bijl et al. (2005) conducted a case report in Severe valvular insufficiency (n=1). Ergotamine tartrate was evaluated on Echocardiographic and clinical findings of valvular insufficiency. Chronic exposure to 2 mg daily ergotamine tartrate in a 67-year-old woman was associated with the development of thickened mitral, pulmonary, and tricuspid valves with severe insufficiency.
Synapse has enriched 10 related papers. Consider them for comparative context: